Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Efficacy and Safety of Turoctocog Alfa for Prophylaxis and Treatment of Bleeding Episodes in Previously Treated Chinese Patients With Haemophilia A

X
Trial Profile

Efficacy and Safety of Turoctocog Alfa for Prophylaxis and Treatment of Bleeding Episodes in Previously Treated Chinese Patients With Haemophilia A

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 05 Nov 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Turoctocog alfa (Primary)
  • Indications Haemophilia A
  • Focus Therapeutic Use
  • Acronyms guardian TM 7
  • Sponsors Novo Nordisk
  • Most Recent Events

    • 02 Jan 2019 Status changed from active, no longer recruiting to completed.
    • 13 Mar 2018 New source identified and integrated (European Clinical Trials Database: EudraCT2013-004791-35)
    • 22 Feb 2018 Planned primary completion date changed from 14 Dec 2018 to 11 Apr 2018.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top